TapewireFind a company

person · Reporting owner

FENNELL GEORGE

Disclosed activity across 1 company

Tapewire entity
42598
SEC CIK
0001521861

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
IDEXX LABORATORIES INC /DEIDXX · Entity 3057Executive Vice PresidentJune 01, 2026June 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

IDEXX LABORATORIES INC /DE

Report date June 01, 2026 · Filed June 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect10,433 Ending reported balance After 2026-06-01 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-06-01 · Exercise / conversion · Acquired 639 · Balance 10,717

Row 2 · 2026-06-01 · Tax withholding · Disposed 284 · Balance 10,433

Restricted Stock UnitSEC Table II · derivative / convertible securityDirect0 Reported balance After 2026-06-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-06-01 · Exercise / conversion · Disposed 639 · Balance 0

F1: Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock and vested in one installment on June 1, 2026.

F2: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock and vested in one installment on June 1, 2026.

F2: Not applicable.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 01, 2026 Filed Jun 2, 2026 21:00 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionRestricted Stock Unit · Derivative 639 Not disclosed Not disclosed
Disclosure

SEC source: 0000874716-26-000114 · wk-form4_1780434004.xml · derivative · entry 3

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 639 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock and vested in one installment on June 1, 2026.

F2 · price: Not applicable.

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock and vested in one installment on June 1, 2026.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of Issuer common stock and vested in one installment on June 1, 2026.

Read SEC document
June 01, 2026 Filed Jun 2, 2026 21:00 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Tax withholdingCommon Stock 284 $566.79 $160,968.36
Disclosure

SEC source: 0000874716-26-000114 · wk-form4_1780434004.xml · nonDerivative · entry 2

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,433

Read SEC document
June 01, 2026 Filed Jun 2, 2026 21:00 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionCommon Stock 639 $0.00 $0.00
Disclosure

SEC source: 0000874716-26-000114 · wk-form4_1780434004.xml · nonDerivative · entry 1

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,717

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 14, 2026 Filed Feb 18, 2026 00:30 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionRestricted Stock Unit · Derivative 204 $0.00 $0.00
Disclosure

SEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · derivative · entry 12

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 612

Underlying: Common Stock · 204 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026.

F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026.

F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026.

Read SEC document
February 14, 2026 Filed Feb 18, 2026 00:30 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionRestricted Stock Unit · Derivative 139 $0.00 $0.00
Disclosure

SEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · derivative · entry 11

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 278

Underlying: Common Stock · 139 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025.

F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025.

F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025.

Read SEC document
February 14, 2026 Filed Feb 18, 2026 00:30 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionRestricted Stock Unit · Derivative 56 $0.00 $0.00
Disclosure

SEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · derivative · entry 10

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56

Underlying: Common Stock · 56 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning February 14, 2024.

F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning February 14, 2024.

F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning February 14, 2024.

Read SEC document
February 14, 2026 Filed Feb 18, 2026 00:30 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionRestricted Stock Unit · Derivative 55 $0.00 $0.00
Disclosure

SEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · derivative · entry 9

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 55 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments beginning February 14, 2023.

F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments beginning February 14, 2023.

F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments beginning February 14, 2023.

Read SEC document
February 14, 2026 Filed Feb 18, 2026 00:30 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Tax withholdingCommon Stock 199 $629.35 $125,240.65
Disclosure

SEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · nonDerivative · entry 5

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,078

F1 · price: Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026.

Read SEC document
February 14, 2026 Filed Feb 18, 2026 00:30 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionCommon Stock 204 $0.00 $0.00
Disclosure

SEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · nonDerivative · entry 4

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,277

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 14, 2026 Filed Feb 18, 2026 00:30 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionCommon Stock 139 $0.00 $0.00
Disclosure

SEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · nonDerivative · entry 3

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,073

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 14, 2026 Filed Feb 18, 2026 00:30 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionCommon Stock 56 $0.00 $0.00
Disclosure

SEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · nonDerivative · entry 2

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,934

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 14, 2026 Filed Feb 18, 2026 00:30 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionCommon Stock 55 $0.00 $0.00
Disclosure

SEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · nonDerivative · entry 1

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,878

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 12, 2026 Filed Feb 18, 2026 00:30 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 GrantRestricted Stock Unit · Derivative 810 $0.00 $0.00
Disclosure

SEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · derivative · entry 8

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 810

Underlying: Common Stock · 810 shares

Expires not disclosed

F4 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027.

F4 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027.

F4 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027.

Read SEC document
February 12, 2026 Filed Feb 18, 2026 00:30 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 GrantIncentive Stock Option (right-to-buy) · Derivative 162 $0.00 Strike: $617.20 $0.00
Disclosure

SEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · derivative · entry 7

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162

Underlying: Common Stock · 162 shares

Expires 2036-02-11

F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030.

Read SEC document
February 12, 2026 Filed Feb 18, 2026 00:30 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 GrantNon-Qualified Stock Option (right-to-buy) · Derivative 3,384 $0.00 Strike: $617.20 $0.00
Disclosure

SEC source: 0000874716-26-000020 · wk-form4_1771374623.xml · derivative · entry 6

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,384

Underlying: Common Stock · 3,384 shares

Expires 2036-02-11

F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027.

Read SEC document
February 10, 2026 Filed Feb 11, 2026 22:01 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative 11,345 $0.00 Strike: $67.85 $0.00
Disclosure

SEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · derivative · entry 12

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,345 shares

Expires 2026-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: Grant of option to buy 11,345 shares of Issuer common stock that vested in five annual installments beginning on February 14, 2017.

Read SEC document
February 10, 2026 Filed Feb 11, 2026 22:01 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 SaleCommon Stock 40 $650.32 $26,012.80
Disclosure

SEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 10

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,823

Read SEC document
February 10, 2026 Filed Feb 11, 2026 22:01 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 SaleCommon Stock 2,809 $649.26 $1,823,771.06
Disclosure

SEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 9

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,863

F7 · price: Represents the weighted average price of the shares sold ranging from a low of $649.05 to a high of $649.72 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Read SEC document
February 10, 2026 Filed Feb 11, 2026 22:01 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 SaleCommon Stock 966 $648.78 $626,720.71
Disclosure

SEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 8

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,672

F6 · price: Represents the weighted average price of the shares sold ranging from a low of $648.02 to a high of $649.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Read SEC document
February 10, 2026 Filed Feb 11, 2026 22:01 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 SaleCommon Stock 1,060 $647.21 $686,039.00
Disclosure

SEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 7

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,638

F5 · price: Represents the weighted average price of the shares sold ranging from a low of $646.825 to a high of $647.69 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Read SEC document
February 10, 2026 Filed Feb 11, 2026 22:01 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 SaleCommon Stock 2,782 $646.23 $1,797,800.45
Disclosure

SEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 6

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,698

F4 · price: Represents the weighted average price of the shares sold ranging from a low of $645.80 to a high of $646.71 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Read SEC document
February 10, 2026 Filed Feb 11, 2026 22:01 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 SaleCommon Stock 2,161 $645.25 $1,394,387.84
Disclosure

SEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 5

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,480

F3 · price: Represents the weighted average price of the shares sold ranging from a low of $644.75 to a high of $645.60 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Read SEC document
February 10, 2026 Filed Feb 11, 2026 22:01 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 SaleCommon Stock 397 $644.02 $255,674.35
Disclosure

SEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 4

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,641

F2 · price: Represents the weighted average price of the shares sold ranging from a low of $643.65 to a high of $644.47 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Read SEC document
February 10, 2026 Filed Feb 11, 2026 22:01 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 SaleCommon Stock 1,130 $643.00 $726,587.06
Disclosure

SEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 3

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,038

F1 · price: Represents the weighted average price of the shares sold ranging from a low of $642.595 to a high of $643.47 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Read SEC document
February 10, 2026 Filed Feb 11, 2026 22:01 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionCommon Stock 11,345 $67.85 $769,758.25
Disclosure

SEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 2

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,168

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 09, 2026 Filed Feb 11, 2026 22:01 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative 1,476 $0.00 Strike: $67.85 $0.00
Disclosure

SEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · derivative · entry 11

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,476 shares

Expires 2026-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: Grant of option to buy 1,476 shares of Issuer common stock that vested on February 14, 2021.

Read SEC document
February 09, 2026 Filed Feb 11, 2026 22:01 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionCommon Stock 1,476 $67.85 $100,146.60
Disclosure

SEC source: 0000874716-26-000005 · wk-form4_1770847267.xml · nonDerivative · entry 1

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,823

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 14, 2025 Filed Feb 19, 2025 02:42 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionRestricted Stock Unit · Derivative 140 $0.00 $0.00
Disclosure

SEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · derivative · entry 12

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 417

Underlying: Common Stock · 140 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2025.

F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2025.

F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2025.

Read SEC document
February 14, 2025 Filed Feb 19, 2025 02:42 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionRestricted Stock Unit · Derivative 57 $0.00 $0.00
Disclosure

SEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · derivative · entry 11

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112

Underlying: Common Stock · 57 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2024.

F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2024.

F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2024.

Read SEC document
February 14, 2025 Filed Feb 19, 2025 02:42 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionRestricted Stock Unit · Derivative 56 $0.00 $0.00
Disclosure

SEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · derivative · entry 10

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55

Underlying: Common Stock · 56 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2023.

F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2023.

F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2023.

Read SEC document
February 14, 2025 Filed Feb 19, 2025 02:42 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionRestricted Stock Unit · Derivative 51 $0.00 $0.00
Disclosure

SEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · derivative · entry 9

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 51 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer. common stock and vested in four annual installments, beginning on February 14, 2022.

F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer. common stock and vested in four annual installments, beginning on February 14, 2022.

F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer. common stock and vested in four annual installments, beginning on February 14, 2022.

Read SEC document
February 14, 2025 Filed Feb 19, 2025 02:42 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Tax withholdingCommon Stock 133 $444.53 $59,122.49
Disclosure

SEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · nonDerivative · entry 5

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,347

Read SEC document
February 14, 2025 Filed Feb 19, 2025 02:42 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionCommon Stock 140 $0.00 $0.00
Disclosure

SEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · nonDerivative · entry 4

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,480

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 14, 2025 Filed Feb 19, 2025 02:42 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionCommon Stock 57 $0.00 $0.00
Disclosure

SEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · nonDerivative · entry 3

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,340

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 14, 2025 Filed Feb 19, 2025 02:42 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionCommon Stock 56 $0.00 $0.00
Disclosure

SEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · nonDerivative · entry 2

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,283

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 14, 2025 Filed Feb 19, 2025 02:42 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionCommon Stock 51 $0.00 $0.00
Disclosure

SEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · nonDerivative · entry 1

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,227

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 13, 2025 Filed Feb 19, 2025 02:42 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 GrantRestricted Stock Unit · Derivative 816 $0.00 $0.00
Disclosure

SEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · derivative · entry 8

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 816

Underlying: Common Stock · 816 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026.

F3 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026.

F3 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2026.

Read SEC document
February 13, 2025 Filed Feb 19, 2025 02:42 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 GrantIncentive Stock Option (right-to-buy) · Derivative 217 $0.00 Strike: $459.76 $0.00
Disclosure

SEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · derivative · entry 7

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 217

Underlying: Common Stock · 217 shares

Expires 2035-02-12

F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2029.

Read SEC document
February 13, 2025 Filed Feb 19, 2025 02:42 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 GrantNon-Qualified Stock Option (right-to-buy) · Derivative 3,415 $0.00 Strike: $459.76 $0.00
Disclosure

SEC source: 0000874716-25-000023 · wk-form4_1739932972.xml · derivative · entry 6

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,415

Underlying: Common Stock · 3,415 shares

Expires 2035-02-12

F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2026.

Read SEC document
February 10, 2025 Filed Feb 11, 2025 22:00 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative 9,986 $0.00 Strike: $79.54 $0.00
Disclosure

SEC source: 0000874716-25-000006 · wk-form4_1739311202.xml · derivative · entry 5

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,986 shares

Expires 2025-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Grant of option to buy 9,986 shares of Issuer common stock that vested in five annual installments beginning on February 14, 2016, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split.

Read SEC document
February 10, 2025 Filed Feb 11, 2025 22:00 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 SaleCommon Stock 9,986 $462.53 $4,618,861.53
Disclosure

SEC source: 0000874716-25-000006 · wk-form4_1739311202.xml · nonDerivative · entry 3

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,176

F1 · price: Represents the weighted average price of the shares sold ranging from a low of $462.4501 to a high of $462.80 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Read SEC document
February 10, 2025 Filed Feb 11, 2025 22:00 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionCommon Stock 9,986 $79.54 $794,286.44
Disclosure

SEC source: 0000874716-25-000006 · wk-form4_1739311202.xml · nonDerivative · entry 2

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,162

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 07, 2025 Filed Feb 11, 2025 22:00 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative 1,256 $0.00 Strike: $79.54 $0.00
Disclosure

SEC source: 0000874716-25-000006 · wk-form4_1739311202.xml · derivative · entry 4

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,256 shares

Expires 2025-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Grant of option to buy 628 shares of Issuer common stock that vested in one installment on February 14, 2020, without giving effect to a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the 'Stock Split'). The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect the Stock Split.

Read SEC document
February 07, 2025 Filed Feb 11, 2025 22:00 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionCommon Stock 1,256 $79.54 $99,902.24
Disclosure

SEC source: 0000874716-25-000006 · wk-form4_1739311202.xml · nonDerivative · entry 1

FENNELL GEORGE · CIK 0001521861 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 22:55 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionRestricted Stock Unit · Derivative 57 $0.00 $0.00
Disclosure

SEC source: 0000874716-24-000035 · wk-form4_1708124098.xml · derivative · entry 14

FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169

Underlying: Common Stock · 57 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2024.

F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2024.

F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2024.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 22:55 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionRestricted Stock Unit · Derivative 56 $0.00 $0.00
Disclosure

SEC source: 0000874716-24-000035 · wk-form4_1708124098.xml · derivative · entry 13

FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111

Underlying: Common Stock · 56 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning ion February 14, 2023.

F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning ion February 14, 2023.

F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning ion February 14, 2023.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 22:55 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionRestricted Stock Unit · Derivative 52 $0.00 $0.00
Disclosure

SEC source: 0000874716-24-000035 · wk-form4_1708124098.xml · derivative · entry 12

FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51

Underlying: Common Stock · 52 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer. common stock and vest in four annual installments beginning on February 14, 2022.

F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer. common stock and vest in four annual installments beginning on February 14, 2022.

F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer. common stock and vest in four annual installments beginning on February 14, 2022.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 22:55 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionRestricted Stock Unit · Derivative 97 $0.00 $0.00
Disclosure

SEC source: 0000874716-24-000035 · wk-form4_1708124098.xml · derivative · entry 11

FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 97 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments beginning on February 14, 2021.

F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments beginning on February 14, 2021.

F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments beginning on February 14, 2021.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 22:55 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 Exercise / conversionRestricted Stock Unit · Derivative 108 $0.00 $0.00
Disclosure

SEC source: 0000874716-24-000035 · wk-form4_1708124098.xml · derivative · entry 10

FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 108 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in five annual installments beginning on February 14, 2020.

F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in five annual installments beginning on February 14, 2020.

F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in five annual installments beginning on February 14, 2020.

Read SEC document
February 14, 2024 Filed Feb 16, 2024 22:55 UTC IDEXX LABORATORIES INC /DE IDXX · Entity 3057 GrantRestricted Stock Unit · Derivative 557 $0.00 $0.00
Disclosure

SEC source: 0000874716-24-000035 · wk-form4_1708124098.xml · derivative · entry 9

FENNELL GEORGE · CIK 0001521861 · SVP, Chief Revenue Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 557

Underlying: Common Stock · 557 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025.

F3 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025.

F3 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vest in four annual installments beginning on February 14, 2025.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.